Sanctuary Advisors LLC acquired a new stake in shares of Cybin Inc. (NYSE:CYBN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 131,252 shares of the company's stock, valued at approximately $36,000.
A number of other hedge funds also recently made changes to their positions in the stock. RA Capital Management L.P. purchased a new position in Cybin in the 1st quarter worth $24,041,000. Rosalind Advisors Inc. lifted its stake in shares of Cybin by 38.3% in the 2nd quarter. Rosalind Advisors Inc. now owns 19,300,000 shares of the company's stock valued at $5,230,000 after acquiring an additional 5,340,000 shares during the last quarter. Ikarian Capital LLC purchased a new stake in Cybin during the 1st quarter valued at about $5,770,000. AWM Investment Company Inc. bought a new position in Cybin during the 1st quarter worth approximately $930,000. Finally, AdvisorShares Investments LLC increased its stake in Cybin by 13.4% in the 2nd quarter. AdvisorShares Investments LLC now owns 1,865,217 shares of the company's stock worth $494,000 after purchasing an additional 220,403 shares during the period. 17.94% of the stock is owned by institutional investors.
Cybin Trading Up 4.0 %
NYSE CYBN traded up $0.44 during trading on Tuesday, hitting $11.36. The company had a trading volume of 110,280 shares, compared to its average volume of 144,680. The firm has a market capitalization of $4.67 billion, a PE ratio of -56.78 and a beta of 0.41. Cybin Inc. has a one year low of $6.50 and a one year high of $28.04.
Cybin (NYSE:CYBN - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) EPS for the quarter. On average, sell-side analysts predict that Cybin Inc. will post -2.85 earnings per share for the current year.
Analysts Set New Price Targets
Several research analysts recently commented on CYBN shares. Canaccord Genuity Group decreased their target price on shares of Cybin from $114.00 to $96.00 and set a "buy" rating on the stock in a research note on Monday, September 23rd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Cybin in a report on Wednesday, July 31st. Finally, HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Cybin in a report on Friday, August 23rd.
Get Our Latest Stock Report on Cybin
About Cybin
(
Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
Recommended Stories
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
